Hikma and Celltrion Healthcare sign new exclusive licensing agreement for Vegzelma® for the Middle East and North Africa region

Post news

Amman, 3January2023 –Hikma Pharmaceuticals PLC(Hikma), the multinational pharmaceutical company,announces a new exclusive licensing agreement with Celltrion Healthcare Co.,Ltd, a global biopharmaceutical company,forVegzelma® (CT-P16, bevacizumab).Under the terms of the agreement, Celltrion Healthcare will be responsible for the development, manufacturing and supply of Vegzelma® and Hikma will be responsible for the commercialisation of the product in all its MENA markets, providing better access to a much needed oncology product.

Vegzelma® is a biosimilar to Avastin® (bevacizumab) and is a U.S. FDA and EMA approved anti-cancer monoclonal antibody treatment.The new agreement builds on Hikma’s long-standing partnership with Celltrion Healthcare and expands Hikma’s biosimilar portfolio, a key focus of its strategy. Through its existing partnership with Celltrion Healthcare, Vegzelma® (CT-P16, bevacizumab)is the seventhbiosimilar to be added to Hikma’s portfolio,which includes the following six products – Truxima® (rituximab), Remsima® (intravenous infliximab), Herzuma® (trastuzumab), Remsima® SC (subcutaneous infliximab), YuflymaTM (adalimumab), and CT-P43(ustekinumab).

Commenting on thelatest agreement with CelltrionHealthcare, Mazen Darwazah, Hikma’s Executive Vice Chairman and President of MENA, said: “We are very excited to be building on our long-term partnership with Celltrion Healthcare. Vegzelma® is an important oncology biosimilar and this partnership will help increase patients’ access to a critical medication in the region”. He added, “The extension of our partnership with Celltrion Healthcare is highly complementary to our existing strategy of building a portfolio of differentiated productsas we continue to focus on putting better health, within reach, every day.”

About Vegzelma® (CT-P16, bevacizumab)

Vegzelma®is an anti-cancer monoclonal antibody treatment biosimilar to Avastin® (bevacizumab). Vegzelma®is a recombinant humanized monoclonal antibody which binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors Flt-1 (VEGFR-1), and kinase insert domain receptor (KDR) (VEGFR-2), on the surface of endothelial cells. In the EU,Vegzelma®is indicated for the treatment of patients with metastatic colorectal cancer, non-small cell lung cancer, metastatic renal cell carcinoma, ovarian cancer, advanced cervical cancer and metastatic breast cancer.